相关实验视频
Updated: Jun 28, 2025

07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
355
西尔德纳菲尔通过抑制Rho激酶活性来改善急性肺栓塞引起的血液动力学变化
The Journal of international medical research
|April 11, 2024
概括
在急性肺栓塞 (APE) 的大鼠模型中,西尔德纳菲尔治疗抑制了Rho激酶激活. 这种作用减少了肺血管收缩,降低了高肺动脉压,为APE提供了潜在的新治疗策略.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 肺部医学 肺部医学
背景情况:
- 急性肺栓塞 (APE) 是一种危及生命的疾病,其特征是肺动脉阻塞.
- 罗激酶 (ROCK) 信号通路在调节血管度方面发挥着关键作用,并与APE的病理生理学有关.
- 目前对APE的治疗重点是恢复血液流动和管理血液动力学不稳定性,但需要新的治疗点.
研究的目的:
- 在大鼠模型中研究西尔德纳菲尔对急性肺栓塞的治疗作用.
- 在APE的背景下,确定西尔德纳菲尔对Rho激酶信号通路的影响.
- 评估西尔代纳菲尔减轻肺血管收缩和降低高血压的能力.
主要方法:
- 斯普拉格-道利大鼠被分配到虚假,肺血栓塞栓症 (PTE) 和西尔代纳菲尔治疗组.
- 西尔德纳菲尔 (0.5毫克/千克/天) 或盐水每天通过输液给药,持续14天.
- 通过注射自身栓塞诱导了APE;使用西式涂抹和ELISA评估了血液动力学参数 (RVSP,MPAP) 和分子标记.
主要成果:
- 在实验诱导APE的老鼠中,Rho激酶信号通路被显著激活.
- 席尔德纳菲尔治疗显著抑制了Rho激酶通路的激活,在老鼠与APE.
- 西尔德纳菲尔的使用导致了肺血管收缩的减少,并降低了肺动脉高血压.
结论:
- 在大鼠模型中,西尔德纳菲尔显示出对急性肺栓塞的保护作用.
- 保护机制涉及抑制Rho激酶活性,导致肺血管收缩减少.
- 这些发现表明,用西尔德纳菲尔向Rho激酶通路可能为管理APE提供一种新的治疗方法.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
150
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
150
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
170
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
160
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
160
Pulmonary Hypertension: Classification and Pathogenesis
173
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
173
Antihypertensive Drugs: Vasodilators
516
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
516

